References
1. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F.. 1973;Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415–55.
https://doi.org/10.1016/0022-510X(73)90175-5.
3. de Rijk M. C., Rocca W. A., Anderson D. W., Melcon M. O., Breteler M. M., Maraganore D. M.. 1997;A population perspective on diagnostic criteria for Parkinson’s disease. Neurology 48(5):1277–81.
https://doi.org/10.1212/WNL.48.5.1277.
5. Haacke E. M., Liu S., Buch S., Zheng W., Wu D., Ye Y.. 2014;Quantitative susceptibility mapping: current status and future directions. Magn Reson Imaging 33(1):1–25.
https://doi.org/10.1016/j.mri.2014.09.004.
9. Jankovic J., McDermott M., Carter J., Gauthier S., Goetz C., Golbeet L., et al. 1990;Parkinson Study Group. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. Neurology 40(10):1529–34.
https://doi.org/10.1212/WNL.40.10.1529.
10. Rosenberg-Katz K., Herman T., Jacob Y., Giladi N., Hendler T., Hausdorff J. M.. 2013;Gray matter atrophy distinguishes between Parkinson disease motor subtypes. Neurology 80(16):1476–84.
https://doi.org/10.1212/WNL.0b013e31828cfaa4.
12. Bagher-Ebadian H., Jiang Q., Ewing J. R.. 2008;A modified fourier-based phase unwrapping algorithm with an application to MRI venography. J Magn Reson Imaging 27(3):649–52.
https://doi.org/10.1002/jmri.21230.
13. Haacke E. M., Cheng N. Y., House M. J., Liu Q., Neelavalli J., Ogg R. J., et al. 2005;Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 23(1):1–25.
https://doi.org/10.1016/j.mri.2004.10.001.
14. Braak H., Tredici K. D., Rub U., de Vos R. A., Jansen Steur E. N., Braak E.. 2003;Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211.
https://doi.org/10.1016/S0197-4580(02)00065-9.
16. Uchida Y., Kan H., Sakurai K., Arai N., Kato D., Kawashima S., et al. 2019;Voxel-based quantitative susceptibility mapping in Parkinson’s disease with mild cognitive impairment. Movement Disorders 34(8):1164–73.
https://doi.org/10.1002/mds.27717.
17. Deh K., Nguyen T. D., Eskreis-Winkler S., Prince M. R., Spincemaille P., Gauthier S., et al. 2015;Reproducibility of quantitative susceptibility mapping in the brain at two field strengths from two vendors. J Magn Reson Imaging 42(6):1592–1600.
https://doi.org/10.1002/jmri.24943.
18. Ravanfar P., Loi S. M., Syeda W. T., Van Rheenen T. E., Bush A. I., Desmond P., et al. 2021;Systematic Review: Quantitative Susceptibility Mapping (QSM) of Brain Iron Profile in Neurodegenerative Diseases. Front. Neurosci 15:618435.
https://doi.org/10.3389/fnins.2021.618435.
19. Mazzucchi S., Frosini D., Costagli M., Del Prete E., Donatelli G., Cecchi P., et al. 2019;Quantitative susceptibility mapping in atypical Parkinsonisms. Neuroimage Clin 24:101999.
https://doi.org/10.1016/j.nicl.2019.101999.
20. Guan X., Xuan M., Gu Q., Xu X., Huang P., Wang N., et al. 2017;Influence of regional iron on the motor impairments of Parkinson’s disease: a quantitative susceptibility mapping study. J Magn Reson Imaging 45(5):1335–42.
https://doi.org/10.1002/jmri.25434.
21. Alves G., Larsen J. P., Emre M., Wentzel-Larsen T., Aarsland D.. 2006;Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord 21(8):1123–30.
https://doi.org/10.1002/mds.20897.
22. Nègre-Pagès L., Grandjean H., Lapeyre-Mestre M., Montastruc J. L., Fourrier A., Lépine J. P., et al. 2010;Anxious and depressive symptoms in Parkinson’s disease: the French cross-sectional DoPaMiP study. Mov Disord 25(2):157–66.
https://doi.org/10.1002/mds.22760.
23. Burn D. J., Landau S., Hindle J. V., Samuel M., Wilson K. C., Hurt C. S., et al. 2012;Parkinson’s disease motor subtypes and mood. Mov Disord 27(3):379–86.
https://doi.org/10.1002/mds.24041.
24. Iijima M., Kobayakawa T., Saito S., Osawa M., Tsutsumi Y., Hashimotoet S., et al. 2011;Differences in odor identification among clinical subtypes of Parkinson’s disease. Eur J Neurol 18(3):425–29.
https://doi.org/10.1111/j.1468-1331.2010.03167.x.
25. Moreau C., Delval A., Defebvre L., Dujardin K., Duhamel A., Petytet G., et al. 2012;Methylphenidate for gait hypokinesia and freezing in patients with Parkinson’s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 11(7):589–96.
https://doi.org/10.1016/S1474-4422(12)70106-0.
26. Shahmaei V., Faeghi F., Mohammadbeigi A., Hashemi H., Ashrafi F.. 2019;Evaluation of iron deposition in brain basal ganglia of patients with Parkinson’s disease using quantitative susceptibility mapping. European Journal of Radiology Open 6:169–74.
https://doi.org/10.1016/j.ejro.2019.04.005.
27. Chen Q., Chen Y., Zhang Y., Wang F., Yu H., Zhang C., et al. 2019;Iron deposition in Parkinson’s disease by quantitative susceptibility mapping. BMC Neurosci 20(23):1–8.
https://doi.org/10.1186/s12868-019-0505-9.